NurPhoto/NurPhoto via Getty Images
- Biogen (NASDAQ:BIIB) is scheduled to announce Q4 earnings results on Tuesday, February 13th, before market open.
- The consensus EPS Estimate is $3.18 (-21.5% Y/Y) and the consensus Revenue Estimate is $2.46B (-3.3% Y/Y).
- Over the last 2 years, BIIB has beaten EPS estimates 88% of the time and has beaten revenue estimates 100% of the time.
- Over the last 3 months, EPS estimates have seen 9 upward revisions and 8 downward. Revenue estimates have seen 10 upward revisions and 6 downward.
- Market sentiment on the stock is mixed as Wall Street analysts maintain a Buy rating, while Seeking Alpha's Quant Rating System, which grades stocks on quantitative measures like valuation and momentum, suggests a Hold.